aspartic acid has been researched along with Stomach Neoplasms in 18 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer." | 9.06 | A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990) |
| "A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer." | 5.06 | A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990) |
| "Twenty-seven patients with colorectal adenocarcinoma, (12) non-small cell bronchogenic carcinoma, (11) gastric adenocarcinoma (3), and adenocarcinoma of unknown primary lesion (1) were treated with the combination of thymidine (TdR), 5-fluorouracil (FU), and N-phosphonacetyl-L-aspartic acid (PALA)." | 3.67 | Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study. ( Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M, 1985) |
| "5-Fluorouracil (5-FU) is widely used in gastric cancer treatment, yet 5-FU resistance remains an important clinical challenge." | 1.72 | Long noncoding RNA OVAAL enhances nucleotide synthesis through pyruvate carboxylase to promote 5-fluorouracil resistance in gastric cancer. ( Han, FH; Hu, H; Huang, J; Luo, ML; Tan, JN; Yang, B; Zhang, W; Zhong, GY; Zhou, SN, 2022) |
| "Globally, gastric cancer is the third most common cancer and the third leading cause of cancer death." | 1.72 | Microbiota and metabolites alterations in proximal and distal gastric cancer patients. ( Chen, X; Chen, Y; Dai, D; Huang, Y; Jin, W; Lin, W; Teng, L; Wang, H; Wang, W; Yang, Y; Zhang, H; Zhang, J; Zhang, Y, 2022) |
| "Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements." | 1.30 | Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. ( Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999) |
| "On the other hand, the pattern in colon cancer was more similar to the colon mucosal layer than the full-thickness layer of normal colon tissue." | 1.29 | Increased aspartate and glutamate levels in both gastric and colon cancer tissues. ( Kita, Y; Komi, N; Miyake, H; Nishi, M; Okada, A; Takehara, H; Yoshida, K, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 6 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, X | 1 |
| Huang, X | 1 |
| Lu, X | 1 |
| Wang, N | 1 |
| Wu, D | 1 |
| Yuan, M | 1 |
| Yin, H | 1 |
| Wang, Q | 1 |
| Wu, DC | 1 |
| Yang, TC | 1 |
| Hu, SX | 1 |
| Candy Chen, HJ | 1 |
| Tan, JN | 1 |
| Zhou, SN | 1 |
| Zhang, W | 1 |
| Yang, B | 1 |
| Zhong, GY | 1 |
| Huang, J | 1 |
| Hu, H | 1 |
| Han, FH | 1 |
| Luo, ML | 1 |
| Yuan, Q | 1 |
| Deng, D | 1 |
| Pan, C | 1 |
| Ren, J | 1 |
| Wei, T | 1 |
| Wu, Z | 1 |
| Zhang, B | 1 |
| Li, S | 2 |
| Yin, P | 1 |
| Shang, D | 1 |
| Yang, Y | 1 |
| Dai, D | 1 |
| Jin, W | 1 |
| Huang, Y | 1 |
| Zhang, Y | 1 |
| Chen, Y | 1 |
| Wang, W | 1 |
| Lin, W | 1 |
| Chen, X | 1 |
| Zhang, J | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Teng, L | 1 |
| Gan, X | 1 |
| Wang, Y | 1 |
| Du, H | 1 |
| Hu, Y | 1 |
| Xing, X | 1 |
| Cheng, X | 1 |
| Yan, Y | 1 |
| Li, Z | 1 |
| Hayashi, R | 1 |
| Kitazawa, K | 1 |
| Sanada, D | 1 |
| Kato, N | 1 |
| Ohkoshi, T | 1 |
| Katsumata, Y | 1 |
| Yamaguchi, S | 1 |
| Hibasami, H | 1 |
| Iwase, H | 1 |
| Yoshioka, K | 1 |
| Takahashi, H | 1 |
| Abasov, IT | 1 |
| Okada, A | 1 |
| Takehara, H | 1 |
| Yoshida, K | 1 |
| Nishi, M | 1 |
| Miyake, H | 1 |
| Kita, Y | 1 |
| Komi, N | 1 |
| Wadler, S | 1 |
| Gleissner, B | 1 |
| Hilgenfeld, RU | 1 |
| Thiel, E | 1 |
| Haynes, H | 1 |
| Kaleya, R | 1 |
| Rozenblit, A | 1 |
| Kreuser, ED | 1 |
| Martino, RL | 1 |
| Fleming, TR | 1 |
| Morrell, LM | 1 |
| Ardalan, B | 1 |
| Richman, SP | 1 |
| Macdonald, JS | 1 |
| Harte, RJ | 1 |
| Matthews, JC | 1 |
| O'Reilly, SM | 1 |
| Tilsley, DW | 1 |
| Osman, S | 1 |
| Brown, G | 1 |
| Luthra, SJ | 1 |
| Brady, F | 1 |
| Jones, T | 1 |
| Price, PM | 1 |
| Mizumura, Y | 1 |
| Matsumura, Y | 1 |
| Hamaguchi, T | 1 |
| Nishiyama, N | 1 |
| Kataoka, K | 1 |
| Kawaguchi, T | 1 |
| Hrushesky, WJ | 1 |
| Moriyasu, F | 1 |
| Kakizoe, T | 1 |
| Windschitl, HE | 1 |
| O'Connell, MJ | 1 |
| Wieand, HS | 1 |
| Krook, JE | 1 |
| Rubin, J | 1 |
| Moertel, CG | 1 |
| Kugler, JW | 1 |
| Pfeifle, DM | 1 |
| Goldberg, RM | 1 |
| Laurie, JA | 1 |
| Chiuten, DF | 1 |
| Miller, A | 1 |
| Valdivieso, M | 1 |
| Loo, TL | 1 |
| Bedikian, A | 1 |
| Bodey, GP | 1 |
| Benvenuto, JA | 1 |
| Freireich, EJ | 1 |
| Kronberger, L | 2 |
| Fink, E | 2 |
| Daill, M | 1 |
| Schindler, R | 1 |
3 trials available for aspartic acid and Stomach Neoplasms
| Article | Year |
|---|---|
Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Fluorour | 1996 |
Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Fluorouracil; | 1996 |
A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer.
Topics: Adult; Aged; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug Evaluation; Drug Sy | 1990 |
15 other studies available for aspartic acid and Stomach Neoplasms
| Article | Year |
|---|---|
The expression and clinical significance of the tRNA aspartic acid methyltransferase 1 protein in gastric cancer.
Topics: Aged; Aspartic Acid; Cell Line, Tumor; Cell Proliferation; Female; Humans; Male; Methyltransferases; | 2021 |
Multiple oxidative and advanced oxidative modifications of hemoglobin in gastric cancer patients measured by nanoflow LC-MS/MS.
Topics: Aspartic Acid; Biomarkers; Chromatography, Liquid; Hemoglobins; Histidine; Humans; Oxidative Stress; | 2022 |
Long noncoding RNA OVAAL enhances nucleotide synthesis through pyruvate carboxylase to promote 5-fluorouracil resistance in gastric cancer.
Topics: Aspartic Acid; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Nucleotides; Oxalo | 2022 |
Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy.
Topics: Alanine; Aspartic Acid; Glutamates; Humans; Immunotherapy; Metabolomics; Neoadjuvant Therapy; Proteo | 2022 |
Microbiota and metabolites alterations in proximal and distal gastric cancer patients.
Topics: Alanine; Arginine; Aspartic Acid; Feces; Glutamates; Hormones; Humans; Metabolomics; Microbiota; RNA | 2022 |
Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer.
Topics: Aspartic Acid; Biomarkers; Humans; Membrane Proteins; Mixed Function Oxygenases; Neoadjuvant Therapy | 2023 |
Diffuse Leukoencephalopathy Associated with Dialysis Disequilibrium Syndrome.
Topics: Acidosis; Aspartic Acid; Coma; Female; Humans; Leukoencephalopathies; Magnetic Resonance Imaging; Ma | 2015 |
Glycyrrhizin induces apoptosis in human stomach cancer KATO III and human promyelotic leukemia HL-60 cells.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Aspartic Acid; Caspase Inhibitors; Cell Line, Tumor; Cys | 2005 |
Chromatographic analysis of free amino acids of gastric juice in patients with cancer and other stomach diseases.
Topics: Adult; Alanine; Amino Acids; Arginine; Aspartic Acid; Chromatography; Cystine; Duodenal Ulcer; Femal | 1967 |
Increased aspartate and glutamate levels in both gastric and colon cancer tissues.
Topics: Aspartic Acid; Colonic Neoplasms; Gastric Mucosa; Glutamates; Glutamic Acid; Humans; Intestinal Muco | 1993 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co | 1999 |
Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Cell Survival; Cisplatin; Colonic Neoplasms; Drug Carriers | 2001 |
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinom | 1985 |
[Urinary excretion of asparagne and aspartate in control subjects and patients with cancer before and after treatment with K-Mg-aspartate].
Topics: Adolescent; Adult; Aged; Asparagine; Aspartic Acid; Breast Neoplasms; Cholecystitis; Female; Humans; | 1972 |
[Potassium-magnesium-aspartate therapy in operated cancer patients].
Topics: Adult; Aged; Anemia, Hypochromic; Aspartic Acid; Body Weight; Breast Neoplasms; Female; Hemoglobinom | 1971 |